Skip Ribbon Commands
Skip to main content
Sign In

24862 Human Herpes Virus-8 Antibody, IgG (HHV8)

Human Herpes Virus-8 Antibody, IgG (HHV8)
Test Code: HHV8SO
Synonyms/Keywords
​Ref Lab Code: 81971, Herpes, Human Herpes Virus 8 (HHV-8), Kaposi's Sarcoma
Useful For
Assessment of serostatus of organ transplant patients to Human Herpesvirus-8 before a procedure to evaluate risk for transmission of virus and subsequent development of Kaposi's sarcoma.​
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​0.25 mL ​0.15 mL
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​Refrigerated (preferred) ​14 days
​Frozen ​14 days
Rejection Criteria
Hemolysis Mild OK; Gross reject​
​Lipemia ​Mild OK; Fross reject
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories​ Monday through Friday​ ​1 day
Immunofluorescence Assay (IFA)​
Reference Lab
Test Information

This test should be regarded as 'Research Use Only'. This test has not been cleared or approved by the U.S. Food and Drug Administration. It may not be covered by insurance and providers need to inform all patients of this prior to ordering. 

For Medicare patients, an Advanced Beneficiary notice (ABN) is required; for Medicaid patients, a Noncovered Services Waiver is required, and for commercial payers, prior authorization should be obtained.  

Human herpesvirus-8 (HHV-8) infections are limited in the general population. The virus was first discovered in Kaposi's sarcoma (KS) lesions and also is known as Kaposi's sarcoma herpesvirus. 

Endemic KS is common in sub-Saharan equatorial Africa, accounting for 10% to 17% of all adult malignancies. Elsewhere KS is rare, occurring primarily in Mediterranean and Eastern European adults. In the United States, KS primarily affects acquired immunodeficiency syndrome (AIDS) patients. Approximately 90% of KS tissues from AIDS patients contain HHV-8 DNA sequences. Sexual transmission of human herpesvirus-8 (HHV-8) may be possible since HHV-8 DNA sequences have been found in the semen of AIDS patients.
 
HHV-8 also is associated with transplantation-associated KS, which occurs in up to 5% of kidney transplant patients. Transmission of HHV-8 through renal allografts has been shown to be a risk factor for transplantation-associated KS.(3,6) Patients who are negative for antibodies to HHV-8 and receive transplanted organs from a donor who has antibodies to HHV-8 are at increased risk for the development of KS post transplantation.
 
HHV-8 also is associated with Bowen’s disease, a malignant squamous cell carcinoma; primary effusion lymphoma; Castleman's disease; and multiple myeloma.
Reference Range Information
Performing Location Reference Range
Mayo Medical Laboratories​ ​Negative (reported as positive or negative)
Interpretation
The IgG antibody seroprevalence rate in the normal population has not been established due to the fact that the human herpesvirus-8 (HHV-8) virus was only recently discovered. Data suggests that the seroprevalence rate in the general population is 5% to 28%.
 
HHV-8 IgG antibody titers of <1:40 in the immunofluorescent assay are considered negative.
 
A positive result indicates the presence of IgG class antibodies to HHV-8; the individual has been infected with this virus sometime in the past.
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​86790
Classification

This test should be regarded as 'Research Use Only'. This test has not been cleared or approved by the U.S. Food and Drug Administration. It may not be covered by insurance and providers need to inform all patients of this prior to ordering. 

For Medicare patients, an Advanced Beneficiary notice (ABN) is required; for Medicaid patients, a Noncovered Services Waiver is required, and for commercial payers, prior authorization should be obtained.  

Synonyms/Keywords
​Ref Lab Code: 81971, Herpes, Human Herpes Virus 8 (HHV-8), Kaposi's Sarcoma
Ordering Applications
Ordering Application Description
​Centricity Human Herpesvirus 8, Ab IgG (81971)​
​Cerner ​None
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​0.25 mL ​0.15 mL
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​Refrigerated (preferred) ​14 days
​Frozen ​14 days
Rejection Criteria
Hemolysis Mild OK; Gross reject​
​Lipemia ​Mild OK; Fross reject
Useful For
Assessment of serostatus of organ transplant patients to Human Herpesvirus-8 before a procedure to evaluate risk for transmission of virus and subsequent development of Kaposi's sarcoma.​
Reference Range Information
Performing Location Reference Range
Mayo Medical Laboratories​ ​Negative (reported as positive or negative)
Interpretation
The IgG antibody seroprevalence rate in the normal population has not been established due to the fact that the human herpesvirus-8 (HHV-8) virus was only recently discovered. Data suggests that the seroprevalence rate in the general population is 5% to 28%.
 
HHV-8 IgG antibody titers of <1:40 in the immunofluorescent assay are considered negative.
 
A positive result indicates the presence of IgG class antibodies to HHV-8; the individual has been infected with this virus sometime in the past.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories​ Monday through Friday​ ​1 day
Immunofluorescence Assay (IFA)​
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​86790
Classification

This test should be regarded as 'Research Use Only'. This test has not been cleared or approved by the U.S. Food and Drug Administration. It may not be covered by insurance and providers need to inform all patients of this prior to ordering. 

For Medicare patients, an Advanced Beneficiary notice (ABN) is required; for Medicaid patients, a Noncovered Services Waiver is required, and for commercial payers, prior authorization should be obtained.  

For most current information refer to the Marshfield Laboratory online reference manual.